Phaim Pharma

Executive Summary

Phaim Pharma is a UK-based biotechnology company founded in 2018, pioneering a novel therapeutic platform called Antigenic Immune Modulation (AIM) to address autoimmune diseases. The platform aims to induce immune tolerance without broad immunosuppression, offering potential disease-modifying or curative therapies. Phaim's lead program targets Type 1 Diabetes (T1D), a condition affecting millions worldwide with limited treatment options beyond insulin replacement. The company's pipeline also includes preclinical programs for psoriasis, rheumatoid arthritis, and multiple sclerosis, leveraging the same immunomodulatory approach. Phaim is advancing its T1D program through early-stage clinical trials, with initial safety and efficacy data anticipated within the next 12-18 months. The AIM platform has shown encouraging preclinical results, suggesting durable antigen-specific tolerance. However, as a private, early-stage company, Phaim faces significant clinical and regulatory risks, including potential safety issues, manufacturing scalability, and competition from other immune tolerance approaches. Success in T1D could validate the platform across multiple autoimmune indications, representing a paradigm shift in treatment. Key near-term catalysts include clinical trial updates and potential orphan drug designations.

Upcoming Catalysts (preview)

• Q1 2027Interim Phase 1/2 Clinical Data for Type 1 Diabetes Program35% success
• Q4 2026Orphan Drug Designation (ODD) for Type 1 Diabetes from FDA or EMA70% success